{"status":"ok","message-type":"work","message-version":"1.0.0","message":{"indexed":{"date-parts":[[2026,2,24]],"date-time":"2026-02-24T08:36:17Z","timestamp":1771922177561,"version":"3.50.1"},"reference-count":5,"publisher":"Springer Science and Business Media LLC","issue":"4","license":[{"start":{"date-parts":[[2022,1,27]],"date-time":"2022-01-27T00:00:00Z","timestamp":1643241600000},"content-version":"tdm","delay-in-days":0,"URL":"https:\/\/www.springer.com\/tdm"},{"start":{"date-parts":[[2022,1,27]],"date-time":"2022-01-27T00:00:00Z","timestamp":1643241600000},"content-version":"vor","delay-in-days":0,"URL":"https:\/\/www.springer.com\/tdm"}],"content-domain":{"domain":["link.springer.com"],"crossmark-restriction":false},"short-container-title":["J. of Cardiovasc. Trans. Res."],"published-print":{"date-parts":[[2022,8]]},"DOI":"10.1007\/s12265-021-10201-0","type":"journal-article","created":{"date-parts":[[2022,1,27]],"date-time":"2022-01-27T00:03:36Z","timestamp":1643241816000},"page":"689-691","update-policy":"https:\/\/doi.org\/10.1007\/springer_crossmark_policy","source":"Crossref","is-referenced-by-count":5,"title":["Wild-Type Transthyretin Cardiac Amyloidosis Is Associated with Increased Antecedent Physical Activity"],"prefix":"10.1007","volume":"15","author":[{"given":"Yi Zhen Joan","family":"Lee","sequence":"first","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"Johana","family":"Fajardo","sequence":"additional","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"Emily","family":"Brown","sequence":"additional","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"Christopher R.","family":"D\u2019Adamo","sequence":"additional","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]},{"ORCID":"https:\/\/orcid.org\/0000-0002-3407-0248","authenticated-orcid":false,"given":"Daniel P.","family":"Judge","sequence":"additional","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]}],"member":"297","published-online":{"date-parts":[[2022,1,27]]},"reference":[{"key":"10201_CR1","doi-asserted-by":"publisher","first-page":"113","DOI":"10.1016\/j.jchf.2013.11.004","volume":"2","author":"SF Mohammed","year":"2014","unstructured":"Mohammed, S. F., Mirzoyev, S. A., Edwards, W. D., et al. (2014). Left ventricular amyloid deposition in patients with heart failure and preserved ejection fraction. JACC Heart Failure, 2, 113\u2013122.","journal-title":"JACC Heart Failure"},{"key":"10201_CR2","doi-asserted-by":"publisher","first-page":"14192","DOI":"10.1074\/jbc.RA118.003990","volume":"293","author":"PP Mangione","year":"2018","unstructured":"Mangione, P. P., Verona, G., Corazza, A., et al. (2018). Plasminogen activation triggers transthyretin amyloidogenesis in vitro. Journal of Biological Chemistry, 293, 14192\u201314199.","journal-title":"Journal of Biological Chemistry"},{"key":"10201_CR3","doi-asserted-by":"publisher","first-page":"340","DOI":"10.1016\/j.cardfail.2016.12.006","volume":"23","author":"VK Ton","year":"2017","unstructured":"Ton, V. K., Bhonsale, A., Gilotra, N. A., et al. (2017). Baseline characteristics predict the presence of amyloid on endomyocardial biopsy. Journal of Cardiac Failure, 23, 340\u2013344.","journal-title":"Journal of Cardiac Failure"},{"key":"10201_CR4","doi-asserted-by":"publisher","first-page":"790","DOI":"10.1123\/jpah.6.6.790","volume":"6","author":"FC Bull","year":"2009","unstructured":"Bull, F. C., Maslin, T. S., & Armstrong, T. (2009). Global physical activity questionnaire (GPAQ): Nine country reliability and validity study. Journal of Physical Activity & Health, 6, 790\u2013804.","journal-title":"Journal of Physical Activity & Health"},{"key":"10201_CR5","doi-asserted-by":"publisher","first-page":"305","DOI":"10.1016\/j.amepre.2010.06.006","volume":"39","author":"SA Carlson","year":"2010","unstructured":"Carlson, S. A., Fulton, J. E., Schoenborn, C. A., & Loustalot, F. (2010). Trend and prevalence estimates based on the 2008 physical activity guidelines for Americans. American Journal of Preventive Medicine, 39, 305\u2013313.","journal-title":"American Journal of Preventive Medicine"}],"container-title":["Journal of Cardiovascular Translational Research"],"original-title":[],"language":"en","link":[{"URL":"https:\/\/link.springer.com\/content\/pdf\/10.1007\/s12265-021-10201-0.pdf","content-type":"application\/pdf","content-version":"vor","intended-application":"text-mining"},{"URL":"https:\/\/link.springer.com\/article\/10.1007\/s12265-021-10201-0\/fulltext.html","content-type":"text\/html","content-version":"vor","intended-application":"text-mining"},{"URL":"https:\/\/link.springer.com\/content\/pdf\/10.1007\/s12265-021-10201-0.pdf","content-type":"application\/pdf","content-version":"vor","intended-application":"similarity-checking"}],"deposited":{"date-parts":[[2022,11,1]],"date-time":"2022-11-01T00:06:58Z","timestamp":1667261218000},"score":1,"resource":{"primary":{"URL":"https:\/\/link.springer.com\/10.1007\/s12265-021-10201-0"}},"subtitle":[],"short-title":[],"issued":{"date-parts":[[2022,1,27]]},"references-count":5,"journal-issue":{"issue":"4","published-print":{"date-parts":[[2022,8]]}},"alternative-id":["10201"],"URL":"https:\/\/doi.org\/10.1007\/s12265-021-10201-0","relation":{},"ISSN":["1937-5387","1937-5395"],"issn-type":[{"value":"1937-5387","type":"print"},{"value":"1937-5395","type":"electronic"}],"subject":[],"published":{"date-parts":[[2022,1,27]]},"assertion":[{"value":"20 September 2021","order":1,"name":"received","label":"Received","group":{"name":"ArticleHistory","label":"Article History"}},{"value":"20 December 2021","order":2,"name":"accepted","label":"Accepted","group":{"name":"ArticleHistory","label":"Article History"}},{"value":"27 January 2022","order":3,"name":"first_online","label":"First Online","group":{"name":"ArticleHistory","label":"Article History"}},{"order":1,"name":"Ethics","group":{"name":"EthicsHeading","label":"Declarations"}},{"value":"All procedures performed in studies involving human participants were in accordance with the ethical standards of the institutional and\/or national research committee and with the 1964 Helsinki declaration and its later amendments or comparable ethical standards.","order":2,"name":"Ethics","group":{"name":"EthicsHeading","label":"Ethical Approval"}},{"value":"Informed consent was obtained from all individual participants included in the study.","order":3,"name":"Ethics","group":{"name":"EthicsHeading","label":"Informed Consent"}},{"value":"Dr. Fajardo reports personal fees from Alnylam, from Eidos, from Pfizer, outside the submitted work; Dr. Judge reports personal fees from 4D Molecular Therapeutics, ADRx, Inc., Cytokinetics, Pfizer, and Tenaya Therapeutics, all outside of the submitted work. MUSC receives clinical trial support from Pfizer, Eidos, and MyoKardia. The remaining authors report nothing to disclose.","order":4,"name":"Ethics","group":{"name":"EthicsHeading","label":"Conflict of Interest"}}]}}